Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease
October 21st 2025Panelists discuss how a triple class–exposed patient with comorbidities like COPD represents an ideal candidate for BCMA-directed bispecific therapy over CAR T-cell therapy due to the ability to titrate dosing and manage respiratory infection risks.
Operationalizing Step-Up Dosing in Outpatient and Inpatient/Outpatient Hybrid Setting
October 14th 2025Panelists discuss how step-up dosing has successfully transitioned from inpatient-only to hybrid and outpatient models using prophylactic tocilizumab and standardized protocols for managing cytokine release syndrome.
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
October 14th 2025Panelists discuss how talquetamab’s unique skin and taste toxicities are manageable through dose modifications and supportive care, with IVIG prophylaxis being crucial for BCMA-targeted but not necessarily GPRC5D-targeted therapies.
Real-World Efficacy and Safety Protocols for Bispecific Antibodies
October 7th 2025Panelists discuss how real-world data consistently show bispecific efficacy matching clinical trial results despite treating higher-risk patients, and how prophylactic interventions have reduced cytokine release syndrome severity.
Sequencing Strategies and Patient Selection for Bispecific Antibodies in RRMM
October 7th 2025Panelists discuss how CAR T-cell therapy should generally precede bispecifics when possible due to T-cell exhaustion concerns, though they agree there are virtually no absolute contraindications to bispecific therapy.
Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM
September 30th 2025Panelists discuss how bispecifics are reversing the historical paradigm of diminishing returns in relapsed/refractory multiple myeloma, achieving 60% to 70% response rates lasting over a year in heavily pretreated patients.
Treatment Decision-Making in Multiple Myeloma at First and Subsequent Relapses
September 30th 2025Panelists discuss how patient preferences for treatment-free intervals are increasingly important in therapy selection, with bispecifics offering potential for response-adapted dosing and early discontinuation while maintaining remissions.
POEMS Syndrome: What's in a Name?
December 15th 2013While the name POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) provides a nice acronym for a collection of seemingly disparate features, the diagnosis does not require that all these elements be present, and many other features are not included.